Nebenwirkungen · Roclanda
Roclanda 50 micrograms/ml + 200 micrograms/ml eye drops, solution · Abschnitt 4.8 · PDF-Seite 7
HOS-144347 · Präparat HOS-099162
Cornea verticillata Cornea verticillata occurred in approximately 13% of the patients in controlled Phase 3 clinical studies. The cornea verticillata seen in latanoprost + netarsudil-treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes in patients. The majority of cornea verticillata resolved upon discontinuation of treatment. The incidence of cornea verticillata was higher in certain subpopulations: elderly (≥65 years) versus non-elderly (18.8 vs. 11.5%); males versus females (18.8 vs. 13.0%) and in white versus other races (21.7 vs. 2.5%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-12T11:25:00Z · SHA-256 87849a8418cacd034df5be09c055fa9f8742a5f7b9c507d3191aa1e9899e02d9 · Passage e7c450e4f5ca29a49837dcd5c616830ba23fcc9358f007c67c565ce8c50f96f8 · Zeichen 9129–9756 im Abschnitt